In this retrospective cohort study, we found that there was a high incidence and mortality in anti-MDA5+DM patients with PJP, while TMP/SMZ prophylaxis significantly reduces PJP risk. Mortality in PJP+ patients is primarily concentrated within the first 3 months, associated with RPILD. The gene discussed is IFIH1; the disease is pneumocystosis.